Tuesday, May 21, 2013

HOPES DIED WITH NEW STUDY

Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer

WE WILL HEAR MORE ABOUT THIS SINCE THE PRODUCT SEEMS TO REACTIVATE A MUTATED P53.  REACTIVATING A MUTATED P53 GENE, REALLY?  THIS COMPOUND IS ACHIEVING A DREAM EFFECT.  CAN YOU IMAGINE RESURRECTING A DEAD GENE, I WANT TO KNOW HOW IT WORKS! 
Post a Comment